[18F]MNI-659
APHP210360
Phase 3 small_molecule active
Quick answer
[18F]MNI-659 for Patients with symptomatic and pre-symptomatic Huntington's disease is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Patients with symptomatic and pre-symptomatic Huntington's disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active